

## MAJOR ARTICLE

# Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy

Bernard Surial<sup>1</sup>, Frédérique Chammartin<sup>2</sup>, José Damas<sup>3</sup>, Alexandra Calmy<sup>4</sup>, David Haerry<sup>5</sup>, Marcel Stöckle<sup>6</sup>, Patrick Schmid<sup>7</sup>, Enos Bernasconi<sup>8</sup>, Christoph A. Fux<sup>9</sup>, Philip Tarr<sup>10</sup>, Huldrych F. Günthard<sup>11,12</sup>, Gilles Wandeler<sup>1\*</sup>, Andri Rauch<sup>1\*</sup>, and the Swiss HIV Cohort Study

<sup>1</sup>Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; <sup>2</sup>Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland; <sup>3</sup>Division of Infectious Diseases, University Hospital of Lausanne, University of Lausanne, Switzerland; <sup>4</sup>Division of Infectious Diseases, Geneva University Hospital, University of Geneva, Switzerland; <sup>5</sup>Chair Positive Council, Switzerland; <sup>6</sup>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Switzerland; <sup>7</sup>Division of Infectious Diseases, Cantonal Hospital of St Gallen, Switzerland; <sup>8</sup>Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland; <sup>9</sup>Division of Infectious Diseases, Cantonal Hospital of Aarau, Aarau, Switzerland; <sup>10</sup>Department of Medicine and Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital Baselland, University of Basel, Switzerland; <sup>11</sup>Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; <sup>12</sup>Institute of Medical Virology, University of Zurich, Switzerland

**Background:** Integrase strand transfer inhibitors (INSTI) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people with HIV (PWH) using a target trial framework, which reduces the potential for confounding and selection bias.

\*Contributed equally

**Corresponding author:** Bernard Surial MD. Department of Infectious Diseases, Inselspital, Bern University Hospital, Bern, Switzerland. Email: [bernard.surial@insel.ch](mailto:bernard.surial@insel.ch)

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

**Methods:** We included Swiss HIV Cohort Study participants who were ART-naïve after 05/2008, when INSTI became available in Switzerland. Individuals were categorized according to their first ART regimen (INSTI vs. other ART) and were followed from ART start until the first of CVD event (myocardial infarction, stroke, or invasive cardiovascular procedure), loss to follow-up, death, or last cohort visit. We calculated hazard ratios and risk differences using pooled logistic regression models with inverse probability of treatment and censoring weights.

**Results:** Of 5362 participants (median age 38 years, 21% women, 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART. Within 4.9 years (IQR 2.4–7.4), 116 CVD events occurred. Starting INSTI-based ART was not associated with an increase in CVD events (adjusted hazard ratio 0.80, 95% confidence interval [CI] 0.46–1.39). Adjusted risk differences between individuals who started INSTI and those who started other ART were -0.17% (95% CI -0.37–0.19) after one year, -0.61% (-1.54–0.22) after 5 years, and -0.71% (-2.16–0.94) after 8 years.

**Conclusions:** In this target trial emulation, we found no difference in short or longer term risk for CVD events between treatment-naïve PWH who started INSTI-based and those on other ART.

**Key words:** antiretroviral therapy; treatment-naïve; myocardial infarction; stroke; integrase strand transfer inhibitor.

## INTRODUCTION

Integrase strand transfer inhibitors (INSTI) have become the mainstay of modern antiretroviral treatment (ART). Compared to non-nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitors (PI), INSTI have improved virological efficacy, better tolerability, and a lower potential for drug-drug interactions[1–3]. In addition, treatment-emergent resistance has become exceedingly rare due to the high genetic barrier to resistance of dolutegravir and bictegravir[4,5]. Therefore, INSTI-based regimens are the preferred recommended initial ART of all major HIV treatment guidelines[6–10], and dolutegravir-based first-line therapy is currently being rolled-out programmatically for people with HIV (PWH) worldwide[11,12].

However, concerns about cardiometabolic complications have emerged in recent years. INSTI-based ART is associated with weight increases among treatment-naïve and -experienced individuals[13–15], and an increased incidence of arterial hypertension and diabetes has been observed in people newly starting INSTI-based ART[16,17]. In addition, a recent analysis of a large collaboration of HIV cohorts in Europe and Australia (RESPOND) found an increased risk for cardiovascular disease (CVD) events with the use of INSTI compared to individuals who did not receive INSTI[18]. The largest increase was observed within the first two years after the initiation of INSTI-based ART, with a return to similar rates in both groups thereafter. As

cardiovascular complications remain a major driver of morbidity and mortality among PWH, the potential contribution of INSTI to cardiovascular disease is a major global public health concern[19].

Although arterial hypertension and obesity can contribute to the development of cardiovascular disease over time, the development of atherosclerosis takes time and is usually not rapidly reversible. Given these pathophysiological mechanisms, the early and transient increase in CVD risk observed in the RESPOND study is unexpected. As the study analyzed treatment-naïve and treatment-experienced individuals together and applied different inclusion criteria for individuals with and without INSTI-based ART, methodological issues such as confounding by indication, immortal time and selection bias may have contributed to the findings.

The target trial framework helps reduce the potential for bias by specifically aligning the start of follow-up (time zero), eligibility and the treatment assignment using observational data[20]. In this study, we aimed to emulate a target trial to estimate the effects of starting INSTI-based ART compared to ART without INSTI on CVD events within the Swiss HIV Cohort Study (SHCS).

## **METHODS**

### **Study design**

We emulated a target trial in which treatment-naïve PWH were assigned to start either INSTI-based or other ART as their first treatment regimen. We used data from the SHCS ([www.shcs.ch](http://www.shcs.ch)), an ongoing prospective cohort established in 1988, which includes close to 80% of individuals who receive ART in Switzerland. Sociodemographic, clinical, and behavioral data as well as laboratory values are prospectively recorded at registration, and every 6 months thereafter using standardized protocols (<http://shcs.ch/292-instructions>). Information on the full ART history and co-medications is collected at every cohort visit using an online data entry tool[21]. All centers' local ethical committees approved the cohort study, and all patients provided written informed consent. Patient representatives were involved in the planning of the study, interpretation of the results, and writing of the manuscript. The reporting of the study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines[22].

### **Eligibility Criteria and Treatment Strategies**

We considered all cohort participants who were HIV treatment-naïve after 1<sup>st</sup> May 2008 (when the first INSTI raltegravir was licensed in Switzerland) and who initiated ART thereafter. Individuals who started unknown ART, those who initiated ART including maraviroc or enfuvirtide, and individuals who had an HIV viral load at treatment-start <50 cp/mL were excluded, as those individuals may not have been treatment-naïve. INSTI-starters included all

participants who received any INSTI-containing ART as first treatment, irrespective of whether other ART components (e.g. NNRTI, PI) were co-administered.

### **Follow-up, Outcomes and Definitions**

Time zero was defined as date of first ART start, and individuals were followed until the first of cardiovascular disease event, loss to follow-up, death, or last cohort visit (database closure on 30 September 2022). Individuals in the INSTI group who stopped INSTI during follow-up were censored at that time, and those who received an initial ART without INSTI were censored when they switched to an INSTI-based therapy (artificial censoring). The outcome of interest was the time to the first CVD event, which included myocardial infarction, stroke, and invasive cardiovascular procedures. CVD events were collected using a dedicated case report form and validated from a senior HIV physician at the cohort site. In addition, central validation was performed using a standardized algorithm blinded to the ART history of the patient[23].

### **Statistical analysis**

We emulated a target trial to compare the risk of CVD events between treatment-naïve PWH who started INSTI and those who started other ART. The time to cardiovascular disease event was analyzed using pooled logistic regression models with inverse probability weighting (IPW) to adjust for confounding, artificial censoring, and loss to follow-up. Stabilized treatment weights were estimated by fitting a logistic regression model with treatment allocation as the outcome, and the following time-fixed confounders as covariates (all evaluated at or prior to ART start): calendar year, age, sex, ethnicity (Caucasian, African origin, and other), HIV transmission group (men who have sex with men [MSM], heterosexual contacts, people who inject drugs [PWID], and other), highest education (high-level, basic, and no professional education), CD4 at ART start ( $\geq 500$  cells/ $\mu\text{L}$ , 350–499 cells/ $\mu\text{L}$ , 200–349 cells/ $\mu\text{L}$ ,  $< 200$  cells/ $\mu\text{L}$ ), HIV viral load at ART start (50–199 cp/mL, 200–100'000 cp/mL,  $> 100$ '000 cp/mL), personal and family history of cardiovascular disease, body mass index (BMI,  $< 18.5$  kg/m<sup>2</sup>, 18.5–24.9 kg/m<sup>2</sup>, 25–29.9 kg/m<sup>2</sup>,  $\geq 30$  kg/m<sup>2</sup>), arterial hypertension, diabetes, total cholesterol, high density lipoprotein (HDL), renal function (estimated glomerular filtration rate [eGFR]  $\geq 90$  mL/min, 60–89 mL/min, or  $< 60$  mL/min), current use of antiplatelet or lipid-lowering drugs, and current use of abacavir (ABC) or tenofovir alafenamide (TAF). Arterial hypertension was defined as a systolic blood pressure  $> 140$  mmHg or a diastolic blood pressure  $> 90$  mmHg on two cohort visits or receiving antihypertensive drugs. Diabetes was defined as an HbA1c level of 6.5% or greater or receiving antidiabetic medication. The eGFR was calculated using the CKD-EPI formula[24]. Follow-up time was included in the model using restricted cubic splines with 3 knots. Similarly, we fit a separate pooled logistic regression model in a person-time format, with loss to follow-up as the outcome, and time-fixed values for calendar year at ART start, age, sex, ethnicity, HIV transmission group, highest education, arterial hypertension, diabetes, renal function, total cholesterol, HDL, and BMI. In addition, time-varying values for smoking, CD4 cell count, HIV RNA, and use of ABC, TAF, lipid-lowering or antiplatelet drug use were

included in the model. Cardiovascular disease risk factors were not included as time-varying covariates as they may lie on the causal path between the exposure and the outcome, and therefore adjusting for those mediating covariates could have led to biased estimates. We fitted a third pooled logistic regression model to estimate weights for artificial censoring, with the same covariates as described in the loss to follow-up model. The loss to follow-up and artificial censoring models were fitted individually for each treatment group (INSTI-based or other ART) as reasons for censoring may have been different between both groups. Finally, we incorporated all weights into a pooled logistic regression model and estimated marginal probabilities of CVD events after six months, one, two, five, and eight years, and calculated risk differences and risk ratios between both groups. We calculated 95% confidence intervals (CI) using nonparametric bootstrapping with 200 samples. In addition, we calculated hazard ratios after 8 years for the main and all subgroup and sensitivity analyses using weighted pooled logistic regression models as described above and used robust sandwich errors to calculate 95% CI. As the missing at random assumption may not have held, we did not impute missing data but included a separate missing category for each covariate with missing information. All analyses were performed with R version 4.1.3[25].

### **Subgroup and Sensitivity Analyses**

To identify whether treatment effects varied according to patient groups, we performed pre-specified subgroup analyses according to sex, age (<65 or ≥65 years), and whether ART included ABC or not. We also performed the following sensitivity analyses to evaluate the robustness of our results: First, we restricted the analysis to individuals who started ART when INSTI became part of the recommended first-line regimens in the European AIDS Clinical Society Guidelines (November 2011)[6], after which INSTI-based ART was prescribed more broadly in Switzerland. Second, we limited the analysis to individuals without a history of CVD in the past, as their risk to develop a subsequent event is higher than the risk of PWH without past CVD events.

## **RESULTS**

Of 13'767 SHCS participants with available follow-up after May 2008, 6027 started their first ART regimen after that date. After excluding 24 individuals with an unknown ART regimen, 7 individuals who received maraviroc as part of their initial ART regimen, and 634 individuals with an undetectable HIV viral load at ART start, the study population included 5362 PWH (**Figure S1**). The median age was 38 years (interquartile range [IQR] 31–47), 1145 (21%) were women, and 817 (15%) were of African origin. Overall, 1837 (34.3%) started INSTI-containing ART, and 3525 (65.7%) started other ART combinations. INSTI uptake was low prior to the inclusion of INSTI as preferred regimen in European guidelines and became the predominant ART component after 2015 (**Figure 1**). The most frequent INSTI initiated was dolutegravir (n = 984, 53%), followed by bictegravir (n = 325, 18%), elvitegravir (n = 298, 16%) and raltegravir

(231, 13%). Of individuals who started INSTI, 152 (8%) additionally received a PI or an NNRTI. Among PWH who started other ART, 1826 (52%) received PI-containing ART, 1595 (45%) received NNRTI-containing ART, and 104 (3%) received a combination thereof. Individuals who started INSTI were less likely to be women, less likely to be of African origin, and had a higher median CD4 nadir compared to individuals with other ART combinations. Smoking status, history of cardiovascular disease, and use of antiplatelet agents were similar in both groups, but INSTI-starters were more likely to have an eGFR <60 mL/min, and to receive abacavir and tenofovir alafenamide (**Table 1**). Among individuals who started ART after 2012, those who started INSTI-based ART were more likely to have arterial hypertension, diabetes, a history of CVD, and an eGFR below 90 mL/min compared with those who started other ART (**Table S1**). The covariate balance before and after IPW is shown in **Figure S2**. Artificial censoring occurred in 111 individuals (6%) who started INSTI and switched to non-INSTI ART during follow-up, and in 2217 individuals (62.9%) who started other ART and switched to INSTI-based therapy during follow-up.

Within a median follow-up of 4.9 years (IQR 2.4–7.4), 116 CVD events occurred: 37 myocardial infarctions (31.9%), 36 strokes (31.0%), and 43 invasive cardiovascular procedures (37.1%, **Table S2**). The unadjusted incidence rate for CVD events was 6.16 per 1000 person-years (PY, 95% confidence interval [CI] 4.64–8.17) for individuals who started INSTI, and 3.54 per 1000 PY (95% CI 2.79–4.49) for individuals who started other ART (hazard ratio [HR] 1.88, 95% CI 1.24–2.84, **Figure 2A**). After adjusting for confounding and informative censoring, the hazard ratio comparing individuals who started INSTI with those who started other ART was 0.80 (95% CI 0.46–1.39, **Figure 2B**). Adjusted risk ratios and risk differences between both treatment groups are presented in **Table 2**. Adjusted risk differences between individuals who started INSTI and those who started other ART ranged from -0.08% (95% CI -0.20 to 0.19) after 6 months to -0.61% (95% CI -1.54 to 0.22) after 5 years.

The impact of starting INSTI compared to other ART was consistent across age groups ( $\geq 65$  years vs. <65 years, p-value for interaction = 0.72), and did not vary according to use of ABC or not (p-value for interaction = 0.91). However, the relative risk of CVD associated with starting INSTI compared to other ART appeared to be lower among women, but this result was not statistically significant (adjusted HR 0.32, 95% CI 0.10–1.11, p-value for interaction = 0.112, **Figure 3**). In a sensitivity analysis excluding individuals with a history of CVD events prior to ART start (n = 72), the adjusted HR for developing a new CVD event with INSTI compared to other ART was 0.74 (95% CI 0.39–1.42, **Figure S3**). When restricting analyses to individuals who started ART after November 2011, when INSTI became part of the recommended initial ART regimens (n = 3216, of whom 1763 started INSTI, and 1453 started other ART), the HR for developing CVD events was similar to the main analysis (adjusted HR 0.94, 95% CI 0.40–2.22, **Figure S4**).

## DISCUSSION

In this nationwide cohort study of 5362 treatment-naïve PWH and a median follow-up of 5 years, we found no difference in risk for developing CVD events between individuals who started an INSTI-based ART and those who started other ART combinations. These findings are reassuring in the context of increasing INSTI use worldwide and support the prioritization of INSTI as the preferred agents in current international guidelines[6–10].

Our main findings contrast with those from RESPOND, who observed a marked increase in CVD risk between 6 and 24 months after the initiation of an INSTI[18]. Whereas the RESPOND study included both treatment-naïve and treatment-experienced cohort participants, we limited our analysis to individuals who started their first ART regimen during the INSTI era. This approach provided better alignment of time zero and reduced the potential for immortal time bias[20]. In addition, whereas the target trial framework required us to apply the same selection criteria for both exposure groups, the RESPOND study only included individuals who were not exposed to INSTI prior to 2012, which may have introduced bias due to the selective left-censoring of individuals who were exposed to INSTI.

A previous registry-based study from the USA documented a lower risk for CVD events among 20'000 treatment-naïve PWH who started INSTI-based ART compared to those who started other ART[26]. Differences in outcome assessment and availability of clinical data may explain some of the discrepancies with the present study, as O'Halloran et al. used administrative data from Medicaid, whereas the SHCS provides detailed longitudinal data with stringent ascertainment of CVD outcomes. The pre-specified subgroup of women appeared to have a lower CVD risk with the use of INSTI in our study, although the confidence intervals were wide and included a null effect. This finding was unexpected, but its interpretation needs to be cautious because it was based on low patient numbers.

Our estimates for the impact on CVD events of starting INSTI compared to other ART combinations differed markedly between unadjusted and adjusted analyses. In part, these differences may be explained by confounding since individuals who started INSTI were more likely to be men and to receive abacavir, factors that were previously associated with an increased CVD risk[27,28]. Furthermore, when examining patient characteristics stratified over time periods, individuals receiving INSTI after 2012 were older and more likely to have additional cardiovascular disease risk factors. In addition, a large proportion of individuals who started other ART eventually switched to INSTI over time. Individuals with comorbidities may have been prioritized to switching to INSTI due to their lower potential for DDI, leading to selection bias in the form of informative censoring. We addressed both confounding and selection bias by applying the target trial framework and using inverse probability of censoring and treatment weights in our study.

We explored the association between INSTI-based ART and CVD risk using a target trial emulation, a framework which reduces the potential for confounding by indication and selection bias. The study was performed using data from the nationally representative cohort of PLWH and showed consistent results across several sensitivity analyses. We relied on long-term follow-up of individuals with and without INSTI-based ART, which allowed us to consider both older and newer generation INSTI. Furthermore, the SHCS follows a very stringent outcome ascertainment based on pre-specified protocols and blinded central validation. However, the relatively low number of CVD events in our study limited the statistical power to detect a difference in CVD risk between groups during each specific time interval and prevented us from performing separate analyses comparing INSTI with PI- or NNRTI-starters, as well as evaluating the role of individual INSTI components. In addition, as our study was restricted to treatment-naïve individuals who started ART, our findings cannot be extrapolated to treatment-experienced individuals who switch to an INSTI-based regimen. Dedicated target trial emulations focused on individuals who switch to INSTI-based ART are needed since a simultaneous switch from TDF to TAF is frequent and may contribute to the cardiovascular disease risk[29]. Furthermore, although we accounted for unmeasured changes in CVD prevention over time by including calendar year in our models, some residual impact on our findings cannot be excluded. Moreover, the difference in follow-up between both groups could potentially lead to selection bias, as individuals who did not experience an event over a longer period may have been healthier and at lower risk for CVD events. However, we accounted for these differences using inverse probability of censoring weighting, which mitigates the impact of differential follow-up time. Finally, even if our results argued against an increase in CVD risk with the use of INSTI, the duration of observation of our study may have been insufficient to capture a gradual increase in CVD risk mediated through INSTI-associated weight increases and arterial hypertension.

In conclusion, we found no evidence of a difference in CVD event risk between treatment-naïve individuals who started INSTI-based ART and those who started other ART combinations. Importantly, the CVD risk was similar between both groups in the short term as well as in the longer term. Similarly designed studies are needed to evaluate the impact of switching to INSTI-based ART among treatment-experienced individuals to further understand the impact of INSTI on cardiometabolic outcomes.

## NOTES

**Authors' contribution:** BS, FC, HFG, GW and AR conceived and designed the study. BS performed the statistical analyses and drafted the initial manuscript. All authors contributed data to the study and to the interpretation of the results and revised the manuscript for substantial intellectual content. All authors read and approved the final manuscript.

**Acknowledgments:** We thank all patients, physicians and nurses associated with the Swiss HIV Cohort Study (SHCS). The members of the SHCS are Abela I, Aebi-Popp K, Anagnostopoulos



A, Battegay M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF (President of the SHCS), Hachfeld A, Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Jackson-Perry D (patient representatives), Kahlert CR (Chairman of the Mother & Child Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Kusejko K (Head of Data Centre), Labhardt N, Leuzinger K, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nemeth J, Nicca D, Notter J, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Salazar-Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory Committee), Tarr P, Trkola A, Wandeler G, Weisser M, Yerly S.

**Funding:** This work was funded by the framework of the SHCS, supported by the Swiss National Science Foundation [SNF grant number 201369, SHCS project number 909], and by the SHCS research foundation. GW was supported by a Professorship from the Swiss National Science Foundation [PP00P3\_211025]. The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians (listed in <http://www.shcs.ch/180-health-care-providers>).

**Potential conflicts of interest:** BS reports financial support to his institution for travel grants from Gilead Sciences and ViiV healthcare, and for advisory boards from Gilead Sciences. DH's institution receives unrestricted educational grants from Abbvie, Gilead, MSD and ViiV Healthcare, AstraZeneca, Roche, Pfizer, GSK. DH has received advisory fees from Gilead and ViiV Healthcare and reports consulting fees from Astra Zeneca and UCB, all outside the submitted work. DH also reports roles on PFMD Executive Committee, Gilde Healthcare Impact Council, EUPATI Advisory committee (chair), Positive Council (Chair), Aids-Hilfe Bern. MS reports support to his institution for advisory boards from Gilead, MSD, ViiV, Pfizer and Moderna, as well as for travel grants from Gilead. EB reports financial support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, ViiV Healthcare, Pfizer, Ely Lilly, and Moderna. EB also reports grants or contracts paid to institution from Merck Sharp & Dohme and participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca. All remuneration went to his home institution and not to EB personally, and all remuneration was provided outside the submitted work. PET's institution reports unrestricted and educational grants from Gilead, ViiV, and MSD, and advisory fees from Gilead and ViiV, and reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD, ViiV, Gilead, all outside the submitted work. HFG has received unrestricted research grants from Gilead Sciences; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, Merck, Johnson and Johnson, Janssen, GSK, Novartis and ViiV Healthcare; a travel grant from Gilead and grants from the Swiss National Science Foundation, Swiss HIV Cohort Study, Swiss HIV Cohort Research Foundation, the Yvonne Jacob Foundation and from National Institutes of Health. GW reports unrestricted research grants from Gilead Sciences and Roche

Diagnostics, as well as travel grants and advisory board/lecture fees from ViiV, Gilead Sciences and MSD, all paid to his institution. AR reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, and Pfizer, and an investigator initiated trial (IIT) grant from Gilead Sciences. AR also reports participation on a Data Safety Monitoring Board or Advisory Board for Moderna. All remuneration went to his home institution and not to AR personally, and all remuneration was provided outside the submitted work. CAF reports Gilead grant for clinical and laboratory follow-up of drug substitution patients regarding HCV in our area, paid to the Department of Infectious Diseases of the Kantonsspital Aarau, Switzerland; support for Advisory Board attendance for Gilead, Menarini, Moderna, MSD, ViiV, paid to institution. PS reports support for attending meetings and/or travel and participation on a Data Safety Monitoring Board or Advisory Board paid to institution from ViiV Healthcare and Gilead Sciences. AC reports unrestricted educational grants from MSD, Gilead, ViiV. All other authors report no conflicts of interest.

## REFERENCES

1. Molina J-M, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. *Lancet HIV* **2015**; 2:e127-36. Available at: [http://dx.doi.org/10.1016/S2352-3018\(15\)00027-2](http://dx.doi.org/10.1016/S2352-3018(15)00027-2).
2. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med* **2013**; 369:1807–1818. Available at: <http://dx.doi.org/10.1056/NEJMoa1215541>.
3. Deutschmann E, Bucher HC, Jaeckel S, et al. Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors. *Clin Infect Dis* **2021**; 73:e2145–e2152. Available at: <http://dx.doi.org/10.1093/cid/ciaa918>.
4. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. *AIDS Rev* **2015**; 17:56–64. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25472016>.
5. Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV* **2019**; 6:e355–e363. Available at: [http://dx.doi.org/10.1016/S2352-3018\(19\)30077-3](http://dx.doi.org/10.1016/S2352-3018(19)30077-3).
6. European AIDS Clinical Society (EACS). Guidelines for the management of people living with HIV. 2022. Available at: [https://www.eacsociety.org/media/guidelines-11.1\\_final\\_09-10.pdf](https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf). Accessed 24 January 2023.
7. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel. *JAMA* **2023**; 329:63–84. Available at: <http://dx.doi.org/10.1001/jama.2022.22246>.
8. World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization, 2021. Available at: <https://www.who.int/publications/i/item/9789240031593>. Accessed 24 January 2023.

9. Waters L, Winston A, Reeves I, et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. *HIV Med* **2022**; 23 Suppl 5:3–115. Available at: <http://dx.doi.org/10.1111/hiv.13446>.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 2022. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv>. Accessed 2 June 2023.
11. Brown JA, Nsakala BL, Mokhele K, et al. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). *HIV Med* **2022**; 23:287–293. Available at: <http://dx.doi.org/10.1111/hiv.13189>.
12. Schramm B, Temfack E, Descamps D, et al. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. *Lancet HIV* **2022**; 9:e544–e553. Available at: [http://dx.doi.org/10.1016/S2352-3018\(22\)00136-9](http://dx.doi.org/10.1016/S2352-3018(22)00136-9).
13. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV* **2020**; 7:e666–e676. Available at: [http://dx.doi.org/10.1016/S2352-3018\(20\)30241-1](http://dx.doi.org/10.1016/S2352-3018(20)30241-1).
14. Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. *Clin Infect Dis* **2020**; 71:1379–1389. Available at: <http://dx.doi.org/10.1093/cid/ciz999>.
15. Bansi-Matharu L, Phillips A, Oprea C, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. *Lancet HIV* **2021**; 8:e711–e722. Available at: [http://dx.doi.org/10.1016/S2352-3018\(21\)00163-6](http://dx.doi.org/10.1016/S2352-3018(21)00163-6).
16. O’Halloran JA, Sahrman J, Parra-Rodriguez L, et al. Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV. *Clin Infect Dis* **2022**; Available at: <http://dx.doi.org/10.1093/cid/ciac355>.
17. Byonanebye DM, Polizzotto MN, Neesgaard B, et al. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. *HIV Med* **2022**; Available at: <http://dx.doi.org/10.1111/hiv.13273>.
18. Neesgaard B, Greenberg L, Miró JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. *Lancet HIV* **2022**; 9:e474–e485. Available at: [http://dx.doi.org/10.1016/S2352-3018\(22\)00094-7](http://dx.doi.org/10.1016/S2352-3018(22)00094-7).
19. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. *Lancet Infect Dis* **2015**; 15:810–818. Available at: [http://dx.doi.org/10.1016/S1473-3099\(15\)00056-0](http://dx.doi.org/10.1016/S1473-3099(15)00056-0).
20. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol* **2016**; 79:70–75. Available at: <http://dx.doi.org/10.1016/j.jclinepi.2016.04.014>.
21. Scherrer AU, Traytel A, Braun DL, et al. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). *Int J Epidemiol* **2022**; 51:33–34j. Available at: <http://dx.doi.org/10.1093/ije/dyab141>.

22. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* **2007**; 147:573–577. Available at: <http://dx.doi.org/10.7326/0003-4819-147-8-200710160-00010>.
23. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* **1994**; 90:583–612. Available at: <http://dx.doi.org/10.1161/01.cir.90.1.583>.
24. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* **2009**; 150:604–612. Available at: <http://dx.doi.org/10.7326/0003-4819-150-9-200905050-00006>.
25. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: 2022. Available at: <https://www.R-project.org/>. Accessed 4 April 2022.
26. O’Halloran JA, Sahrman J, Butler AM, Olsen MA, Powderly WG. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV. *J Acquir Immune Defic Syndr* **2020**; 84:396–399. Available at: <http://dx.doi.org/10.1097/QAI.0000000000002357>.
27. Kuhn FE, Rackley CE. Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention. *Arch Intern Med* **1993**; 153:2626–2636. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8250659>.
28. Jaschinski N, Greenberg L, Neesgaard B, et al. Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV. *AIDS* **2023**; 37:467–475. Available at: <http://dx.doi.org/10.1097/QAD.0000000000003373>.
29. Drechsler H, Ayers C, Bedimo R. Tenofovir disoproxil fumarate withdrawal and cardiovascular risk. *Lancet HIV* **2023**; 10:e8–e9. Available at: [http://dx.doi.org/10.1016/S2352-3018\(22\)00362-9](http://dx.doi.org/10.1016/S2352-3018(22)00362-9).

## TABLES

**Table 1 Characteristics of study participants at antiretroviral therapy start**

Characteristic	INSTI-based ART, N = 1’837	Other ART, N = 3’525
<b>Female sex</b>	291 (16%)	854 (24%)
<b>Median age, years (IQR)</b>	39 (31-50)	38 (31-46)
<b>African origin</b>	199 (11%)	618 (18%)
<b>HIV transmission group</b>		
MSM	1’099 (60%)	1’846 (52%)
Heterosexual contacts	550 (30%)	1’269 (36%)
PWID	74 (4.0%)	196 (5.6%)
Other	114 (6.2%)	214 (6.1%)
<b>Highest education</b>		
High-level education	835 (45%)	1’355 (38%)
Basic education	874 (47%)	1’915 (55%)
No prof. education	100 (5%)	219 (6%)

Characteristic	INSTI-based ART, N = 1'837	Other ART, N = 3'525
<i>missing</i>	28 (1%)	36 (1%)
<b>AIDS-defining disease</b>	196 (11%)	395 (11%)
<b>Median CD4 nadir, cells/μL (IQR)</b>	330 (188-482)	278 (171-372)
<b>CD4 nadir, cells/μL</b>		
≥500 cells/μL	360 (20%)	300 (8.5%)
350-499 cells/μL	365 (20%)	613 (17%)
200-349 cells/μL	411 (22%)	1'166 (33%)
<200 cells/μL	405 (22%)	907 (26%)
<i>missing</i>	296 (16%)	539 (15%)
<b>HIV-RNA at ART start</b>		
50-199 cp/mL	87 (4.7%)	217 (6.2%)
200-100'000 cp/mL	991 (54%)	1'911 (54%)
>100'000 cp/mL	594 (32%)	986 (28%)
<i>missing</i>	165 (9.0%)	411 (12%)
<b>ART start year</b>		
before 2012	81 (4.4%)	2'140 (61%)
2012-2016	809 (44%)	1'270 (36%)
after 2016	947 (52%)	115 (3.3%)
<b>History of CVD</b>	28 (1.5%)	44 (1.2%)
<b>Family history of CVD</b>	209 (11%)	352 (10.0%)
<b>Diabetes</b>	39 (2.1%)	62 (1.8%)
<b>Arterial hypertension</b>	189 (10%)	350 (9.9%)
<b>Renal function (eGFR)</b>		
≥90 mL/min	1'203 (65%)	2'227 (63%)
60-89 mL/min	365 (20%)	531 (15%)
<60 mL/min	42 (2.3%)	54 (1.5%)
<i>missing</i>	227 (12%)	713 (20%)
<b>Median eGFR, mL/min (IQR)</b>	104 (90-115)	106 (93-118)
<b>Smoking status</b>		
current	842 (46%)	1'660 (47%)
never	783 (43%)	1'535 (44%)
past	192 (10%)	322 (9.1%)
<i>missing</i>	20 (1.1%)	8 (0.2%)
<b>Median BMI, kg/m<sup>2</sup> (IQR)</b>	23.6 (21.4-26.3)	23.2 (21.2-25.7)
<b>BMI category</b>		
Normal (18.5-24.9 kg/m <sup>2</sup> )	858 (47%)	1'624 (46%)
Overweight (25-29.9 kg/m <sup>2</sup> )	374 (20%)	606 (17%)
Obese (≥30 kg/m <sup>2</sup> )	121 (6.6%)	178 (5.0%)
Underweight (<18.5 kg/m <sup>2</sup> )	78 (4.2%)	152 (4.3%)
<i>missing</i>	406 (22%)	965 (27%)
<b>Use of antiplatelet agent</b>	34 (1.9%)	54 (1.5%)
<b>Use of lipid-lowering drug</b>	48 (2.6%)	62 (1.8%)

Characteristic	INSTI-based ART, N = 1'837	Other ART, N = 3'525
Use of abacavir	430 (23%)	411 (12%)
Use of tenofovir alafenamide	730 (40%)	48 (1.4%)

INSTI = Integrase strand transfer inhibitor, ART = antiretroviral therapy, IQR = interquartile range, MSM = men who have sex with men, PWID = persons who inject drugs, CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, BMI = body mass index.

**Table 2 Cardiovascular disease event risks after starting antiretroviral therapy**


Time since ART start	INSTI		Other ART		Adjusted <sup>1</sup> risk difference	Adjusted <sup>1</sup> risk ratio
	Unadjusted CVD event risk	Adjusted <sup>1</sup> CVD event risk	Unadjusted CVD event risk	Adjusted <sup>1</sup> CVD event risk		
6 months	0.28%	0.08%	0.12%	0.16%	-0.08% (-0.20 to 0.19)	0.49 (0.11 to 3.35)
1 year	0.28%	0.17%	0.33%	0.34%	-0.17% (-0.37 to 0.19)	0.49 (0.20 to 1.86)
2 years	0.68%	0.38%	0.54%	0.75%	-0.37% (-0.72 to 0.09)	0.50 (0.28 to 1.17)
5 years	2.38%	1.32%	1.51%	1.93%	-0.61% (-1.54 to 0.22)	0.68 (0.37 to 1.14)
8 years	6.94%	2.64%	2.61%	3.34%	-0.71% (-2.16 to 0.94)	0.79 (0.49 to 1.34)

ART = antiretroviral therapy, INSTI = integrase strand transfer inhibitor

<sup>1</sup>Adjusted for confounding and informative censoring (refer to methods for a detailed list of covariates)

## FIGURE LEGENDS

**Figure 1** Use of INSTI as initial antiretroviral treatment over time




Patients starting ART:

Other	388	605	651	496	427	405	220	136	82	50	32	18	10	4
INSTI	3	34	19	25	30	77	166	279	257	245	222	203	121	132


Representation of the proportion of treatment-naïve individuals who received integrase strand transfer inhibitor (INSTI)-based or other antiretroviral therapy (ART) combinations as first-line treatment in the Swiss HIV Cohort Study (SHCS) over time. After INSTI were recommended as the preferred initial regimens in major treatment guidelines (vertical dashed line), uptake of INSTI rapidly increased: In 2021, 96% of individuals starting ART received INSTI compared with 4% who received other ART.

**Figure 2** Cumulative cardiovascular disease event incidence after starting antiretroviral therapy



Number at risk


INSTI	1813	1615	1398	1165	945	722	504	275	130
Other	3549	3161	2855	2522	2227	1933	1582	1261	976



**Panel A** shows a cumulative incidence curve representing the unadjusted cumulative incidence of cardiovascular disease (CVD) events over time. **Panel B** shows survival curves of cumulative CVD incidence, adjusted for confounders and informative censoring (see methods section for a full list of covariates). Shaded areas represent 95% confidence intervals.



**Figure 3** Impact of INSTI on cardiovascular disease risk overall and by pre-specified subgroups



The forest plot shows adjusted hazard ratios (95% confidence intervals) of the prespecified subgroup analyses. All analyses are adjusted for confounders and informative censoring (see methods section for a full list of covariates). **INSTI** = integrase strand transfer inhibitors, **ABC** = abacavir.